Chemically induced sarcomas of inbred mice are immunogenic in syngeneic hosts, and preimmunization with tumor cells leads to resistance to subsequent tumor transplants. The tumor rejection antigens (TRAs) that mediate this reaction are highly specific for each tumor; cross-protection between different syngeneic sarcomas is rare. Isolated membrane and cytosol fractions from two antigenically distinct BALB/c sarcomas, Meth A and CMS5, have TRA activity, and biochemical characterization of the active components from the cytosol and plasma membranes of these two tumors identified a glycoprotein ofMr 96,000. Immunization with unfractionated Meth A cytosol frequently leads to tumor enhancement, but the tumor-enhancing activity (TEA) is lost on fractionation and TRA activity becomes demonstrable. As Meth A and CMS5 lack expression of murine leukemia virus (MuLV) antigens or transcripts, MuLV-related antigens cannot be involved in the TEA or TRA activities of these tumors. In contrast to the lack of cross-reactivity between Meth A and CMS5 TRAs in transplantation tests, rabbit antiserum prepared against the Meth A Mr 96,000 antigen reacted with the CMS5 Mr 96,000 antigen. In view of the biochemical and antigenic similarities of Meth A and CMS5 TRAs, we propose that structurally related but distinct Mr 96,000 glycoproteins are expressed in chemically induced sarcomas and that these molecules are responsible for the individually specific immunogenicity of these tumors.
biochemical characterization of the active components from the cytosol and plasma membranes of these two tumors identified a glycoprotein ofMr 96,000. Immunization with unfractionated Meth A cytosol frequently leads to tumor enhancement, but the tumor-enhancing activity (TEA) is lost on fractionation and TRA activity becomes demonstrable. As Meth A and CMS5 lack expression of murine leukemia virus (MuLV) antigens or transcripts, MuLV-related antigens cannot be involved in the TEA or TRA activities of these tumors. In contrast to the lack of cross-reactivity between Meth A and CMS5 TRAs in transplantation tests, rabbit antiserum prepared against the Meth A Mr 96,000 antigen reacted with the CMS5 Mr 96,000 antigen. In view of the biochemical and antigenic similarities of Meth A and CMS5 TRAs, we propose that structurally related but distinct Mr 96,000 glycoproteins are expressed in chemically induced sarcomas and that these molecules are responsible for the individually specific immunogenicity of these tumors.
The tumor rejection antigens (TRAs) of chemically induced sarcomas of mice have been the object of much interest since their discovery more than two decades ago (1) (2) (3) (4) . TRAs are demonstrated by their ability to induce resistance to tumor transplants in specifically immunized syngeneic recipients. A striking feature of TRAs is their diversity; each sarcoma appears to have its own unique antigen or set of antigens, because immunization against any one tumor generally offers no protection against any other syngeneic sarcoma. The identity of TRAs and the basis for their extensive polymorphism are unclear. Among the possibilities that have been suggested are (i) preexisting antigenic diversity in normal cells (5) , (ii) reexpression of embryonic or fetal antigens (6) (7) (8) (9) , (iii) antigens encoded by altered or derepressed genes of the major histocompatibility complex (MHC) (10) , (iv) antigens encoded by genes linked to the immunoglobulin heavy chain (Igh) locus (11), (v) antigens related to recombinant murine leukemia viruses (MuLV) (12, 13) , and (vi) epigenetic errors in membrane assembly (14) .
To facilitate the isolation and identification of TRAs, considerable effort has gone into developing serological probes to detect these antigens. This has proven to be extremely difficult, and only in the case of BALB/c Meth A sarcoma have antibodies to surface antigens with TRArelated characteristics been repeatedly generated (12, 15, 16) . For this reason, attempts to isolate TRAs have relied on transplantation tests to monitor antigen purification, and DuBois et al. (17) (18) (19) and other workers (20) (21) (22) (23) have characterized cellular fractions with TRA activity. In the present report, we describe the purification and characterization of TRAs from two antigenically distinct BALB/c sarcomas and compare their properties with antigens isolated by other investigators.
MATERIALS AND METHODS
Mice and Tumor Lines. Inbred BALB/c mice were obtained from our mouse colonies. BALB/c sarcomas Meth A and CMS5 have been described by DeLeo et al. (12) .
Preparation of Cytosol and Plasma Membranes. Subcellular fractions were obtained by the method of DuBois et al. (19) .
Column Chromatography. Concanavalin A (Con A)-Sepharose, DEAE-Sepharose CL-6B, and FPLC Mono Q columns were obtained from Pharmacia. Immunoaffinity chromatography was performed by the method of Livingston (24) . For details, see Fig. 2 legend. NaDodSO4/PAGE. NaDodSO4/PAGE was performed according to Laemmli (25) and the gels were stained with silver by the method of Oakley et al. (26) .
Protein Electrophoretic Blotting. Protein blotting was carried out by the method of Towbin et al. (27) .
Cell Surface Labeling. Cells were surface labeled by lactoperoxidase-mediated iodination (28) . RESULTS Tumor Rejection Assays. Two transplantable sarcomas of BALB/c origin, Meth A ascites and CMS5, were chosen for these studies because of their well-defined immunogenicity, lack of cross-protective antigens, and absence of MuLVrelated antigens. Our standard protocol involves immunizing mice by two injections one week apart followed by a tumor challenge 1 week after the second injection. 
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To purify the TRA from Meth A cytosol, the Con A-bound fraction was applied to a DEAE-Sepharose CL-6B column and fractions were eluted with a 0-1 M NaCl gradient. The TRA activity eluted as a broad peak between 300 and 400 mM NaCl. This peak was applied to a Mono Q FPLC column and the resulting fractions were tested for TRA activity (Fig. 2) . Though more than one fraction showed TRA activity, the major activity eluted at 400 mM NaCl. This preparation was analyzed by NaDodSO4/PAGE and showed a prominent protein band of Mr 96,000 and a minor species of Mr 150,000 under both reducing and nonreducing conditions (Fig. 3) . The two bands were individually excised from a preparative gel and the proteins were eluted, dialyzed against PBS, and tested for TRA activity. The TRA has also been purified from the soluble fraction of Meth A plasma membranes. This fraction was applied to a Con A-Sepharose column, and the bound and unbound fractions were tested for TRA activity. Although a small proportion of the activity bound to the column, most of the activity appeared in the unbound fraction. The Con Aunbound material was then applied to a DEAE-Sepharose CL-6B column, from which TRA activity eluted at 300 mM NaCl. This fraction was applied to a Mono Q FPLC column, and TRA activity eluted at 300 mM NaCl. NaDodSO4/PAGE analysis of this fraction showed a major protein band of Mr 96,000.
Purification and Identification of CMS5 TRA. To determine whether TRAs of other tumors would have the characteristics of Meth A TRA, we purified TRA from the antigenically distinct sarcoma CMS5. Cytosol and plasma membrane fractions of CMS5 were tested in tumor rejection assays. Plasma membrane preparations reproducibly showed TRA activity, but the level of activity in individual cytosol preparations varied from undetectable to significant. However, irrespective of whether or not unfractionated cytosol showed TRA activity, fractionation on a Con A-Sepharose column consistently revealed TRA activity in the Con A-bound fraction and, to a more variable degree, in the Con A-unbound fraction. Con A-bound fractions were applied to a DEAE-Sepharose CL-6B column, and fractions eluting at 200-300 mM NaCl were observed to have TRA activity. This material was applied to a Mono Q FPLC column, and the fractions eluting between 200 and 320 mM NaCl showed TRA activity. All fractions from the Mono Q column were analyzed by NaDodSO4/PAGE, and a prominent band of Mr 96,000 was observed in fractions eluting between 200 and 320 mM NaCl but not in other fractions (Fig. 3) . Only fractions containing the Mr 96,000 band elicited resistance to CMS5 in tumor rejection assays, and purified CMS5 Mr 96,000 antigen containing no other bands had TRA activity.
Specificity of Meth A and CMS5 TRAs. TRA was purified from the cytosol of Meth A and CMS5 by sequential Con A-Sepharose and DEAE-Sepharose chromatography. As shown in Fig. 4 (Fig. 3 ).
An immunoaffinity column was prepared by covalently linking the IgG fraction of the rabbit antiserum to activated Sepharose. A preparation of Meth A TRA was applied to the column and unbound and eluted fractions were analyzed for TRA activity. The eluted fraction was active in the Meth A tumor rejection assay, whereas the unbound fraction was depleted of TRA activity. NaDodSO4/PAGE of the eluted Immunology: Srivastava et al. fraction showed a single band of Mr 67,000; this molecule reacted strongly with the rabbit anti-Meth A Mr 96,000 serum in protein blots. It seems likely that the pH 11.5 buffer used to elute the bound fraction is responsible for generating the Mr 67,000 fragment from the Mr 96,000 component. immunized with the Con A-bound fraction of Meth A cytosol in doses ranging from 1 unit to 50 units per mouse and were challenged with the 125,000 Meth A cells. The results indicate that adxriinistration of TRA causes tumor immunity only within a restricted dose range. Administration of 10 units had virtually no effect on tumor growth, while administration of 20 units caused tumor enhancement (Fig. 5 ). Mice injected with 50 units died within 12-24 hr; trivial explanations for this toxicity (e.g., residual buffer, NaDodSO4, or high protein concentrations) have been ruled out.
DISCUSSION
The Mr 96,000 components isolated from Meth A and CMS5 display the immunogenicity and specificity expected ofTRAs of chemically induced sarcomas-i.e., they confer immunity against substantial tumor challenges comparable to immunity elicited by trocar pieces and they do not protect against challenges with an independently induced syngeneic sarcoma. DuBois et al. (19) have also used Meth A as a source of TRA and have concluded that a Mr 75,000 component represents the active antigen. Table 1 summarizes the characteristics of the Mr 75,000 antigen (subsequently revised to Mr 82,000) described by DuBois et al. (19) 
